Novartis

NovartisNovartis provides innovative healthcare solutions that address the evolving needs of patients and societies. Headquartered in Basel, Switzerland, Novartis offers a diversified portfolio to best meet these needs: innovative medicines, eye care and cost-saving generic pharmaceuticals. Novartis is the only global company with leading positions in these areas. In 2015, the Group achieved net sales of USD 49.4 billion, while R&D throughout the Group amounted to approximately USD 8.9 billion (USD 8.7 billion excluding impairment and amortization charges). Novartis Group companies employ approximately 118,000 full-time-equivalent associates. Novartis products are available in more than 180 countries around the world.

www.novartis.com

Novartis RSS Channel

Filters
List of articles in category Novartis
Title Published Date
Global study by Novartis and European Migraine and Headache Alliance reveals 60% of employed people with severe migraine miss, on average, a week of work per month 03 July 2018
Novartis Clear about Psoriasis survey data highlights challenges psoriasis patients face to achieve goal of clear skin 26 June 2018
Novartis receives positive CHMP opinion for Aimovig® (erenumab) for the prevention of migraine 04 June 2018
Patient-reported outcomes tool revealed significant improvement in symptom frequency and quality of life domains with Entresto® 28 May 2018
Novartis data at ASCO and EHA reinforce company's commitment to reimagining cancer 21 May 2018
Alcon Cares Project 100 commits to reducing cataract blindness globally 08 May 2018
Novartis launches FocalView app, providing opportunity for patients to participate in ophthalmology clinical trials from home 26 April 2018
Novartis renews commitment to malaria elimination, investing USD 100 million to research and develop next-generation antimalarials 17 April 2018
Phase III data in The Lancet show Novartis siponimod significantly improves outcomes in patients with secondary progressive MS 26 March 2018
Novartis announces changes to the Executive Committee to support strategic priorities 13 March 2018
Novartis expands alliance with Science 37 to advance virtual clinical trials program 09 March 2018
Novartis and Pear Therapeutics to develop digital therapeutics for patients with schizophrenia and multiple sclerosis 01 March 2018
Novartis appoints Elizabeth Barrett as Oncology Head 16 January 2018
Novartis drug Tasigna® (nilotinib) secures EU approval for first and second-line treatment of Ph+ CML-CP in children 23 November 2017
Novartis drug Rydapt® (midostaurin) receives EU approval for newly diagnosed FLT3-mutated acute myeloid leukemia (AML) and three types of advanced systemic mastocytosis (SM) 20 September 2017
Novartis appoints Bertrand Bodson as Chief Digital Officer 25 August 2017
Novartis receives approval in the EU for Cosentyx label update, includes long term superiority data versus Stelara in psoriasis 06 July 2017
New patient survey highlights need for more action to help severe asthma patients gain control of their disease 19 June 2017
Novartis Foundation and partners launch initiative to tackle hypertension and its root causes in low-income urban communities 17 May 2017
Novartis drug combination Tafinlar® + Mekinist® receives EU approval for BRAF V600-positive advanced non-small cell lung cancer (NSCLC) 04 April 2017